At the SITC 2016 Annual Meeting & Associated Programs, the society hosted a Value Summit in collaboration with the American Society of Clinical Oncology (ASCO) to continue the ongoing dialogue around the value of cancer immunotherapy.
Below is a synopsis of the program:
As health care costs continue to rise, there has been intense interest in better understanding the value of current therapeutic strategies for the treatment of cancer. Historically, most oncologic drugs were evaluated for clinical benefit and potential toxicity prior to regulatory approval.
Because many cancer drugs were associated with low response rates and high rates of adverse events, the high price of cancer drug development has recently been called into question. Warren Buffet is credited with saying that “price is what you pay, value is what you get”. Thus, a mandate to include an assessment of the real value of new cancer agents has become a high priority for clinicians, patients, payors and regulatory bodies in the United States and around the world.
Tumor immunotherapy is a new form of cancer treatment that has emerged as a clinically beneficial alternative for many types of cancer. Tumor immunotherapy has been frequently characterized by durable responses and a very different pattern of adverse events compared to traditional cytotoxic chemotherapy or targeted therapies. To date, most value assessments in oncology have not focused on tumor immunotherapy resulting in uncertainty about the real value associated with this form of cancer treatment. This summit will discuss the issues of value with respect to tumor immunotherapy bringing a variety of different perspectives to the table, including academic physicians, patient advocates, regulatory agencies and third party payors. In addition to articulating the unique features of tumor immunotherapy and the value proposition for this form of treatment, the summit is expected to result in a referendum on future directions and priorities for better defining the full value of tumor immunotherapy for patients with cancer.
To learn more about this program and to access slides from the presentation, visit this website.
This final session of SITC 2015 brought together leaders in the field to initiate important dialogue on the value of cancer immunotherapy treatment. A variety of stakeholders, including academic physicians, industry experts, patient advocates and regulatory agencies shared their diverse perspectives about this important discussion. In addition to articulating the unique features of tumor immunotherapy and the value proposition for this form of treatment, the session resulted in a referendum on future directions and priorities for better defining the full value of tumor immunotherapy for patients with cancer.
For further insight into this session, please view our press release.
This may be due to an alternate immune checkpoint, CD200 (OX2) checkpoint blockade. The immuneosuppressive CD200 protein shuts down the immune system through multiple mechanisms (Xiong et al, 2016). We demonstrated that human glioblastoma in the top ...
While I agree with Stephanie's detailed account, simply put checkpoint molecules are a signature of exhausted/ chronically stimulated lymphocytes and therefore serves as a feedback mechanism to mitigate the immune activation from entering an overdrive ...
Hi Stephanie many thanks for your ample reply. It makes sense indeed in order to secure self-antigens. However, is immune system evasion by means of immune checkpoint a matter of quality or quantity? I mean is there a cutoff for "normal"CTLA4, PD1 levels ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org